Letters

ATAC trial: reporting interim results is not helpful

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7402.1329-b (Published 12 June 2003) Cite this as: BMJ 2003;326:1329
  1. Heather Goodare ([email protected]), chair,
  2. Clare Dimmer ([email protected]), secretary,
  3. Kathy Page ([email protected]), treasurer
  1. Breast UK (Breast-cancer Research Ethics and Advocacy Strategy), Horsham, West Sussex RH13 6DF
  2. Breast UK Waterlooville, Hants PO7 6LA
  3. Breast UK Lower Layham, Suffolk IP7 5NA

    EDITOR—We should like to raise some concerns about the ATAC (arimidex, tamoxifen alone or in combination) trial, which was reported on in the Lancet after only half the time stipulated in the protocol (2.5 years instead of 5).1 Ravdin has raised important points: “Early reporting rules can powerfully …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe